Literature DB >> 27535388

Diagnosis and Molecular Classification of Lung Cancer.

Jaime Rodriguez-Canales1, Edwin Parra-Cuentas1, Ignacio I Wistuba2.   

Abstract

Lung cancer is a complex disease composed of diverse histological and molecular types with clinical relevance. The advent of large-scale molecular profiling has been helpful to identify novel molecular targets that can be applied to the treatment of particular lung cancer patients and has helped to reshape the pathological classification of lung cancer. Novel directions include the immunotherapy revolution, which has opened the door for new opportunities for cancer therapy and is also redefining the classification of multiple tumors, including lung cancer. In the present chapter, we will review the main current basis of the pathological diagnosis and classification of lung cancer incorporating the histopathological and molecular dimensions of the disease.

Entities:  

Keywords:  Lung cancer; Molecular targets; Pathology classification

Mesh:

Year:  2016        PMID: 27535388     DOI: 10.1007/978-3-319-40389-2_2

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  58 in total

1.  ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.

Authors:  Guoxin Hou; Zhimin Lu; Yanyu Bi; Jingjing Deng; Xinmei Yang
Journal:  Med Oncol       Date:  2022-02-12       Impact factor: 3.064

Review 2.  The Impact of ACE and ACE2 Gene Polymorphisms in Pulmonary Diseases Including COVID-19.

Authors:  Iphigenia Gintoni; Maria Adamopoulou; Christos Yapijakis
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

3.  Tumor Suppressor 4.1N/EPB41L1 is Epigenetic Silenced by Promoter Methylation and MiR-454-3p in NSCLC.

Authors:  Qin Yang; Lin Zhu; Mao Ye; Bin Zhang; Peihe Zhan; Hui Li; Wen Zou; Jing Liu
Journal:  Front Genet       Date:  2022-06-20       Impact factor: 4.772

4.  LINC01578 affects the radiation resistance of lung cancer cells through regulating microRNA-216b-5p/TBL1XR1 axis.

Authors:  Peirong Wang; Linchun Ke; Chuanshu Cai; Feng Dong
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

5.  The importance of endobag use with incision-protective devices in VATS lung resection: a preliminary study.

Authors:  Carlos Andrés Latorre Noguera; Agnaldo José Lopes; Ivan Mathias Filho; Claudio Higa; Rodolfo Acatauassú Nunes; Carlos Eduardo Teixeira Lima; Eduardo Haruo Saito
Journal:  BMC Res Notes       Date:  2022-05-10

6.  Short- and long-term outcomes in elderly patients with locally advanced non-small-cell lung cancer treated using video-assisted thoracic surgery lobectomy.

Authors:  Like Zhang
Journal:  Ther Clin Risk Manag       Date:  2018-11-08       Impact factor: 2.423

7.  STAT1-induced upregulation of lncRNA KTN1-AS1 predicts poor prognosis and facilitates non-small cell lung cancer progression via miR-23b/DEPDC1 axis.

Authors:  Changmin Liu; Xiaoming Li; Yanzhang Hao; Feng Wang; Zhiwen Cheng; Haitao Geng; Dianzhong Geng
Journal:  Aging (Albany NY)       Date:  2020-05-12       Impact factor: 5.682

8.  Platelet-Activating Factor-Receptor Signaling Mediates Targeted Therapies-Induced Microvesicle Particles Release in Lung Cancer Cells.

Authors:  Shreepa J Chauhan; Anita Thyagarajan; Yanfang Chen; Jeffrey B Travers; Ravi P Sahu
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

9.  MicroRNA-155-5p promotes cell proliferation and invasion in lung squamous cell carcinoma through negative regulation of fibroblast growth factor 9 expression.

Authors:  Feng Liu; Qing Mao; Shaojin Zhu; Junlan Qiu
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

Review 10.  Heterogeneity of Glucose Transport in Lung Cancer.

Authors:  Cesar A Martinez; Claudio Scafoglio
Journal:  Biomolecules       Date:  2020-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.